IMB Dx, Inc. (KOSDAQ:461030)

-2.59% (1Y)

Market Cap	116.21B
Revenue (ttm)	3.51B
Net Income (ttm)	-8.39B
Shares Out	14.02M
EPS (ttm)	-598.56
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,906
Average Volume	36,764
Open	8,290.00
Previous Close	8,290.00
Day's Range	8,240.00 - 8,440.00
52-Week Range	7,710.00 - 23,500.00
Beta	n/a
RSI	43.08
Earnings Date	n/a

About IMB Dx

IMB Dx, Inc. provides liquid biopsy platform in South Korea. It offers AlphaLiquid Platform that provides circulation-tumor DNA-based precision diagnostics solutions across various stages of cancer for patients, survivors, and individuals; and AlphaLiquid 100 test, a tool that enables the detection of biomarkers across 118 cancer-related genes through one blood test. The company also provides CancerDetect, a liquid biopsy platform for the early detection of cancer recurrence post-surgery; and CancerFind, a blood-based test for various cancer ea...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 461030

Financial Performance

In 2024, IMB Dx's revenue was 3.41 billion, a decrease of -15.40% compared to the previous year's 4.03 billion. Losses were -9.58 billion, -8.06% less than in 2023.